Search results for " Pulmonary and Respiratory Medicine"

showing 10 items of 70 documents

Eligibility of real-life patients with copd for inclusion in rcts: A commentary

2017

Randomized clinical trials (RCTs) are performed to provide evidence to support treatment decisions. Based on the nature of those studies and the need to avoid confounding factors, it has been argued that the population selected in RCTs only partially represents the real-life population. This assumption casts doubts on the applicability of the results provided by RCTs in the management of individuals with an established diagnosis of COPD, and advocates the need for complementary studies with a pragmatic design. Herein, we comment on the recent article published by Halpin and colleagues on the Journal [Halpin et al, Respir Res 17:120, 2016], in which higher rates of inclusions in RCTs for COP…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPediatricsInclusion (disability rights)PopulationAlternative medicineEligibility DeterminationCOPD researchClinical practiceSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionPulmonary Disease Chronic Obstructive03 medical and health sciencesClinical trials0302 clinical medicineRandomized controlled triallawHumansMedicine030212 general & internal medicineEligibility DeterminationIntensive care medicineeducationRandomized Controlled Trials as TopicCOPDeducation.field_of_studybusiness.industryPatient SelectionConfoundingmedicine.diseaseClinical trialClinical trial030228 respiratory systemCommentaryClinical practice; Clinical trials; COPD research; Pulmonary and Respiratory Medicinebusiness
researchProduct

Branch ligatures and blood aspiration for post-traumatic superficial temporal artery pseudoaneurysm: surgical technique

2014

The aim of this study is to report a new minimally invasive technique of superficial temporal artery (STA) pseudoaneurysm treatment. Several surgical options have been employed to treat STA pseudoaneurysms. To address this rare condition, the employed techniques are ligation and excision of the aneurysm, endovascular coil embolization or percutaneous ultrasound-guided thrombin injection. Between techniques no significant differences are reported in terms of outcomes. The decision to adopt a technique depends on STA pseudoaneurysm morphology and surgeon preference. In the present report, STA pseudoaneurysm afferent and efferent branches were identified by ultrasound in a 92-year-old female. …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPercutaneousDecompression610 Medicine & healthSettore MED/22 - Chirurgia Vascolaredigestive system2705 Cardiology and Cardiovascular MedicinePseudoaneurysmAneurysmmedicine.arterymedicineCraniocerebral TraumaHumansMinimally Invasive Surgical Procedurescardiovascular diseasesLigationAged 80 and over10042 Clinic for Diagnostic and Interventional Radiologybusiness.industryTemporal Artery Pseudoaneurysm Post-traumaticGeneral Medicinemedicine.diseaseSuperficial temporal artery10020 Clinic for Cardiac Surgery2746 SurgerySurgeryCardiac surgeryTemporal Arteriesmedicine.anatomical_structure2740 Pulmonary and Respiratory MedicineCardiothoracic surgerycardiovascular systemSurgeryFemaleRadiologyCardiology and Cardiovascular MedicinebusinessAneurysm FalseArtery
researchProduct

Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice

2016

Chronic spontaneous urticaria (CSU) is a skin disease that predominantly affects adults, especially women aged 20 to 40 years, and is characterized by the recurrent appearance of localized or widespread wheals, angioedema or both, without apparent external trigger. 1 , 2 Severe CSU has a detrimental effect on the quality of life and is a frequent cause of absenteeism from school and work. [3] The pathogenesis of CSU is not well understood, and it appears to have an autoimmune cause in approximately one-third of patients. [4] Guidelines for the management of CSU recommend the use of second-generation antihistamines, with the addition of leukotriene receptor antagonists, cyclosporine, or omal…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyUrticariabusiness.industryImmunologyMEDLINEOmalizumabOmalizumabDermatologyClinical PracticeAnti-Allergic Agents; Chronic Disease; Humans; Omalizumab; Urticaria; Immunology and Allergy; Pulmonary and Respiratory Medicine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineChronic disease030228 respiratory systemAnti-Allergic AgentsChronic DiseaseHumansMedicineImmunology and AllergybusinessAnti-Allergic Agentsmedicine.drug
researchProduct

Should we use gait speed in COPD, FEV 1 in frailty and dyspnoea in both?

2016

Frailty is a progressive physiological decline in multiple organ systems marked by loss of function, loss of physiological reserve and increased vulnerability to disease [1]. Biological (inflammation and loss of hormones), clinical ( e.g. sarcopenia and osteoporosis) and social factors are involved in frailty onset, evolution and prognosis [2, 3]. Links between frailty, dyspnoea and chronic respiratory diseases represent a novel and practical approach

Pulmonary and Respiratory Medicinemedicine.medical_specialty[SDV]Life Sciences [q-bio]OsteoporosisDiseaseIdoso FragilizadoDispneia03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineInternal medicineForced Expiratory VolumemedicineHumans030212 general & internal medicineLoss functionOrgan systemComputingMilieux_MISCELLANEOUSAgedAged 80 and overCOPDFrailtybusiness.industrymedicine.disease3. Good healthGait speedWalking SpeedPreferred walking speedDyspnea030228 respiratory systemSarcopeniaPhysical therapyCardiologyDoença Pulmonar Obstrutiva CrónicaVolume Expiratório ForçadoAged; Aged 80 and over; Dyspnea; Forced Expiratory Volume; Frailty; Humans; Pulmonary Disease Chronic Obstructive; Walking Speed; Pulmonary and Respiratory MedicinebusinessHuman
researchProduct

Management of acute pulmonary embolism: towards a (truly) global reach

2021

The study by Z. Zhai and colleagues provides an overview of the developments observed as risk-adapted management strategies for acute pulmonary embolism have been progressively introduced and optimised in the Chinese healthcare systemhttps://bit.ly/3swGht2

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industry10031 Clinic for AngiologyMEDLINE610 Medicine & healthmedicine.diseasePulmonary embolism2740 Pulmonary and Respiratory MedicineHealth careAcute DiseaseMedicineHumansbusinessIntensive care medicinePulmonary Embolism
researchProduct

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct

The puzzle of metabolic effects of obstructive sleep apnoea in children.

2016

In adults, obstructive sleep apnoea (OSA) is often associated with metabolic alterations. Although obesity is a major culprit [1], large epidemiological studies have reported a metabolic risk associated with OSA that is independent of obesity. In particular, meta-analyses have shown that effective treatment of OSA by continuous positive airway pressure (CPAP) improves glycaemic control in both diabetic [2] and nondiabetic patients [3]. In obese children with obstructive sleep apnoea insulin resistance is common while lipids do not show a clear pattern

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.medical_treatmentPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioCulprit03 medical and health sciences0302 clinical medicineInsulin resistancestomatognathic systemInternal medicineEpidemiologymedicineHumansContinuous positive airway pressureChildTonsillectomySleep Apnea Obstructivebusiness.industryMedicine (all)Metabolic riskmedicine.diseaseSleep in non-human animalsObesitynervous system diseasesrespiratory tract diseasesChild; Humans; Polysomnography; Sleep Apnea Obstructive; Tonsillectomy; Medicine (all); Pulmonary and Respiratory MedicineEndocrinology030228 respiratory systemMetabolic effectsCardiologybusiness030217 neurology & neurosurgeryHumanThe European respiratory journal
researchProduct

Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma

2019

AIMS: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. METHODS: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. STAKEHOLDERS: Incl…

SENTINEL NETWORKAllergyRespiratory Medicine and AllergyReviewWORLD-HEALTH-ORGANIZATIONDiseaseRhinitis.App; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis0302 clinical medicineQUALITY-OF-LIFEPRECISION MEDICINEDG SantéHealth careMedicine and Health SciencesGRADING QUALITYImmunology and AllergyMedicinemHealthRinitisLungmedicin och allergiRhinitis0303 health sciencesThe MASK study groupPublic sectorApp ; Asthma ; Care pathways ; MASK ; mHealth ; Rhinitis ; DG SanteMOBILE TECHNOLOGY3. Good healthALLERGIC RHINITISCHRONIC RESPIRATORY-DISEASESRinitemHealthCare pathwaysEUROPEAN SYMPOSIUMCLINICAL-PRACTICE GUIDELINESLife Sciences & BiomedicinePulmonary and Respiratory Medicinemedicine.medical_specialtyMASKImmunologySettore MED/10 - Malattie Dell'Apparato RespiratorioPredictive medicine03 medical and health sciencesQuality of life (healthcare)App -MASKAsma030304 developmental biologyAsthmaARIAScience & TechnologyCare pathwaybusiness.industryChange managementCorrectionDG SanteRC581-607medicine.diseaseAsthma030228 respiratory systemApp; Asthma; Care pathways; DG Santé; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineFamily medicineImmunologic diseases. AllergybusinessApp[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine

2017

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, whose burden is expected to increase in the next decades, because of numerous risk factors, including the aging of the population. COPD is both preventable and treatable by an effective management including risk factor reduction, prevention, assessment, and treatment of acute exacerbations and co-morbidities. The available agents approved for COPD treatment are long-acting or ultra-long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) bronchodilators, as well as inhaled corticosteroids (ICS) in combination with LABAs. ICS use has been restricted only to selected COPD patients by th…

Settore MED/10 - Malattie dell'Apparato RespiratorioAlternative medicineCOPD; drivers; inhaled corticosteroids; prescribing; Pulmonary and Respiratory MedicineCOPD; drivers; inhaled corticosteroids; prescribingAdrenal Cortex HormonePulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesDrug Combination030212 general & internal medicinePractice Patterns Physicians'Precision Medicineeducation.field_of_studyCOPDEvidence-Based MedicineprescribingdriversBronchodilator AgentsDrug CombinationsMuscarinic AntagonistPractice Guidelines as TopicGuideline AdherenceHumanAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinemedicine.medical_specialtydriverPopulationSocio-culturaleInhaled corticosteroidsMuscarinic Antagonistsinhaled corticosteroid03 medical and health sciencesAdministration InhalationmedicineHumansCOPDMedical prescriptionRisk factorIntensive care medicineeducationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentPrimary Health Carebusiness.industryPrecision medicinemedicine.disease030228 respiratory systemObservational studyinhaled corticosteroidsbusiness
researchProduct

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life

2016

Marco Contoli,1 Paolo Solidoro,2 Fabiano Di Marco,3,4 Nicola Scichilone,5 Angelo Corsico,6 Fulvio Braido,7 Pierachille Santus4,8 1Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy; 2Cardiovascular and Thoracic Department, Città della Salute, Turin, Italy; 3Department of Health Sciences, University of Milan, Milan, Italy; 4Respiratory Unit, San Paolo Hospital, Milan, Italy; 5Department of Internal Medicine, Section of Pulmonology (DIBIMIS), University of Palermo, Palermo, Italy; 6Department of Molecular Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 7Allergy and Respiratory Diseases Clinic, DIMI, University of G…

Time FactorsReviewdaily symptomsAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineBronchodilatorMedicine030212 general & internal medicineLungCOPDHealth PolicyTropaneLAMAGeneral MedicineBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeTolerabilityChronic inflammatory responsePublic HealthHumanPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime Factormedicine.drug_classBronchoconstrictionSocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease03 medical and health sciencesAclidinium bromideaclidiniumAclidinium; COPD; Daily symptoms; LAMA; Quality of life; Bronchoconstriction; Bronchodilator Agents; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome; Tropanes; Quality of LifeInternal medicineSeverity of illnessAnticholinergicCOPDHumansAdverse effectBronchodilator Agentlcsh:RC705-779business.industryEnvironmental and Occupational HealthDaily symptomPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemRecovery of Functionmedicine.diseasequality of life030228 respiratory systemPhysical therapybusinessTropanesInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct